Will be very interesting to see if any patients will be interviewed if and when some start feeling better.
That would not harm the blinding of the trial, they won’t know what dose if any they are on, but depending on how many interviews it may give some insights of what to expect at readout.
Must admit though I doubt we will be inundated with patient interviews.
Market Data 
Markets 
AI
